Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MNGIE patients needed to map disease course and speed up future treatments

NCT ID NCT07627217

Knowledge-focused Sponsor: University of Cambridge Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study gathers medical information from people with MNGIE, a rare genetic disease that affects the nerves and digestive system. Researchers want to learn how the disease progresses and find better ways to measure it. Up to 50 patients worldwide can join, and no new treatments or procedures are given. The results will help design future clinical trials for potential therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The minimum required data for inclusion, and to allow verification of duplicate patients, will include year of birth, sex, and method of biochemical or genetic diagnosis of MNGIE as defined under the inclusion criteria. Patients may be living or deceased.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: All patients with a laboratory-confirmed TP deficiency: * any age or stage of disease; living or deceased * both previously published and unpublished patients * symptomatic and asymptomatic patients * TP deficiency defined by a and/or b and/or c: 1. Homozygous or compound heterozygous pathogenic or likely pathogenic mutations in the TYMP gene; and/or 2. Decreased TP enzyme activity \<20% of normal; and/or 3. Increased plasma dThd\> 1 µmol/L, or increased plasma dUrd \> 5 µmol/L. Exclusion Criteria: * There are no formal exclusion criteria for this retrospective observational study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitochondrial neurogastrointestinal encephalomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mitochondrial neurogastrointestinal encephalomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mitochondrial neurogastrointestinal encephalomyopathy (mngie) MNGIE

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Clinical Neurosciences

    RECRUITING

    Cambridge, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.